| Wednesday
| Thursday | Friday
| Saturday |
| SUNDAY,
DECEMBER 14, 2008 |
| 7:00-9:00 |
POSTER DISCUSSION 9 & CONTINENTAL BREAKFAST - Ballroom B
|
| |
Angiogenesis (#901-907) |
901-907 |
| |
|
| 7:00-9:00 |
POSTER SESSION 6 & CONTINENTAL BREAKFAST– Exhibit Hall B
(#6001-6153) |
| |
 |
|
| |
Detection/Diagnosis |
| |
Molecular, Functional and Novel Imaging
Other
|
6001-6008
6009-6011 |
| |
Tumor Cell and Molecular Biology |
| |
Cellular Mechanisms
Gene Therapy
Metabolism and Breast Cancer
Systems Biology of Breast Cancer
|
6012-6021
6022-6023
6024-6030
6031-6033
|
| |
Prognosis and Response Predictions |
| |
Response Predictions - Biomarkers and
Other Factors
|
6034-6075
|
| |
Risk, Epidemiology and Prevention |
| |
Epidemiology - Population Studies
|
6076-6099
|
| |
|
|
| |
Social, Behavioral, Economic and Outreach Studies |
|
| |
Cost Effectiveness |
6100-6111 |
| |
|
|
| |
Treatment |
|
| |
Advanced Chemotherapy
Advanced Endocrine Therapy
Managing Therapy-Related Toxicities
Other
|
6112-6125
6126-6134
6135-6144
6145-6153 |
| |
|
| 9:00-12:00 |
GENERAL SESSION 7– Exhibit Hall D |
| |
Sandra Swain, MD, Co-Moderator
Washington Hospital Center, Washington, DC
and
Richard Crownover, MD, PhD, Co-Moderator
UT Health Science Center San Antonio, San Antonio, TX |
| |
|
| 9:00 |
71. IGF-IR targeted therapy for the treatment of metastatic breast
cancer
Sachdev D, Pelzer A, Yee D. University of Minnesota, Minneapolis, MN. |
| |
|
| 9:15 |
72. MCF-7 cells selected for acquired resistance to an anti IGF-IR
antibody remain sensitive to fulvestrant and to an IGFIR tyrosine
kinase
inhibitor (TKI)
Zhang X, Seidel B, LaPara KS, Yee D. University of Minnesota, Minneapolis,
MN. |
| |
|
| 9:30 |
73. Loss of PTEN engages ErbB3 and IGF-I receptor signaling to
promote antiestrogen resistance in breast cancer
Miller TW, Perez-Torres M, Wu H, Shyr Y, Guix M, Jiang A, Stal O, Arteaga CL.
Vanderbilt Univ, Nashville, TN; Linkoping Univ, Linkoping, Sweden. |
| |
|
| 9:45 |
74. Local-regional recurrence with and without radiation afterneoadjuvant
chemotherapy and mastectomy for T3N0 breast cancer
patients
Nagar H, Mittendorf EA, Strom EA, Perkins G, Oh JL, Tereffe W, Woodward
W, Gonzalez-Angulo A, Hunt K, Buchholz T, Yu TK. MD Anderson Cancer
Center, Houston, TX. |
| |
|
| 10:00 |
75. NSABP B-30: definitive analysis of patient outcome from a
randomized
trial evaluating different schedules and combinations
of adjuvant therapy
containing doxorubicin, docetaxel and
cyclophosphamide in women with
operable, node-positive breast
cancer
Swain SM, Jeong J-H, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L,
Atkins JN, Polikoff J, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas
EP, Ganz PA, Land SR, Wolmark N. National Surgical Adjuvant Breast
and Bowel Project (NSABP), Pittsburgh, PA; Washington Cancer Inst. /
Washington Hosp. Cntr., Washington, DC; Univ. of Pittsburgh, Pittsburgh,
PA; Allegheny Gen. Hosp., Pittsburgh, PA; Colorado Cancer Res. Prog.,
Denver, CO; Kaiser Permanente Northern California, Vallejo, CA; Southeast
Cancer Control Consortium CCOP, Goldsboro, NC; Southern California
Kaiser Permanente, San Diego, CA; ECOG, Philadelphia, PA; Massachusetts
Gen. Hosp. Cancer Cntr, Boston, MA; SWOG, Ann Arbor, MI; Arizona Cancer
Cntr / Univ. of AZ / Arizona Health Sciences Center, Tucson, AZ; NCCTG,
Rochester, NY; Mayo Clinic, Jacksonville, FL; Aultman Health Foundation,
Canton, OH; UCLA Jonsson Comprehensive Cancer Cntr, Los Angeles, CA.
|
| |
|
| 10:15 |
76. NSABP B-30: definitive analysis of quality of life (QOL) and
menstrual
history (MH) outcomes from a randomized trial evaluating
different schedules
and combinations of adjuvant therapy containing
doxorubicin, docetaxel
and cyclophosphamide in women with
operable, node-positive breast cancer
Ganz PA, Land SR, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins
JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP,
Wolmark N, Swain SM. National Surgical Adjuvant Breast and Bowel Project
(NSABP), Pittsburgh, PA; UCLA Jonsson Comp. Cancer Cntr, Los Angeles, CA;
Univ of Pittsburgh, Pittsburgh, PA; Allegheny Gen. Hospital, Pittsburgh, PA;
Colarado Cancer Res Prog, Denver, CO; Kaiser Permanente, Northern Calif.,
Vallejo, CA; Southeast Cancer Control Consortium CCOP, Goldsboro, NC;
Southern California Kaiser Permanente, San Diego, CA; ECOG, Philadelphia,
PA; Massachusetts Gen. Hospital Cancer Cntr, Boston, MA; 12SWOG, Ann
Arbor, MI; Arizona Cancer Cntr/Univ of AZ/Arizona Health Sciences Cntr,
Tucson, AZ; NCCTG, Rochester, MN; Mayo Clinic Jacksonville, Jacksonville,
FL; Aultman Health Foundation, Canton, OH; Washington Cancer Inst./
Washington Hosp. Cntr., Washington, DC. |
| |
|
| 10:30 |
77. BCIRG 005 main efficacy analysis: a phase III randomized
trial comparing docetaxel in combination with doxorubicin and
cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide
followed by docetaxel (AC
→T) in women with Her-2/neu negative
axillary lymph node positive early breast cancer
Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, Saleh M,
Sehdev S, Provencher L, Von Minckwitz G, Semiglazov V, Slamon D, Tabah-
Fisch I, Buyse M, Riva A, Taupin H, Sauter G, Mackey J, On behalf of the
BCIRG005 Investigators. GBG, Neu-Isenburg, Germany; Maria Sklodowska-
Curie, Warsaw, Poland; ICORG, Dublin, Ireland; UCLA, Los Angeles, CA; MSC
Inst., Krakow, Poland; GEICAM, Madrid, Spain; Univ.Alabama, Birmingham,
AL; William Osler Health Ctr, Brampton, Canada; CHA-Hopital Du St
Sacrement, Quebec, Canada; NN Petrov Research Inst., St Petersbourg,
Russian Federation; Sanofi-Aventis, Paris, France; IDDI, Louvain-La-Neuve,
Belgium; TRIO/CIRG, Paris, France; Univ. Med Centre, Hamburg, Germany;
Cross Cancer Inst., Edmonton, Canada. |
| |
|
| 10:45 |
78. Superiority of sequential docetaxel over standard FE100C in
patients
with intermediate risk breast cancer: survival results of the
randomized
intergroup phase III trial EC-Doc
Nitz U, Huober J, Lisboa B, Harbeck N, Fischer H, Moebus V, Hoffmann
G, Augustin D, Weiss E, Gluz O, Kuhn W. West German Study Group,
Moenchengladbach, Germany; Kantonspital, St. Gallen, Switzerland; Unikl.
HH-Eppendorf, Hamburg, Germany; KH Rechts d. Isar, Muenchen, Germany;
EKO, Oberhausen, Germany; STK Frankfurt Hoechst, Frankfurt, Germany; St.
Josefs H., Wiebaden, Germany; Kl. Deggendorf, Deggendorf, Germany; KKH
Boeblingen, Boeblingen, Germany; Unik. Bonn, Bonn, Germany. |
| |
|
| 11:00 |
79. Integrated meta-analysis on 6402 patients with early breast
cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab
containing chemotherapy
von Minckwitz G, Kaufmann M, Kümmel S, Fasching P, Eiermann W,
Blohmer J-U, Costa SD, Sibylle L, Dietmar V, Untch M. GBG Forschungs
GmbH, Neu-Isenburg, Germany; Univ., Frankfurt, Germany; Univ., Essen,
Germany; Univ., Erlangen, Germany; Rotkreuz Hosp., Munich, Germany;
Breast Center, St. Gertrauden, Berlin, Germany; Univ., Magdeburg, Germany;
Helios Hosp., Berlin, Germany. |
| |
|
| 11:15 |
80. Pegylated liposomal doxorubicin (PLD) plus docetaxel
significantly
improves time to progression (TTP) compared with
docetaxel (D) monotherapy
in patients with advanced breast cancer
(ABC) treated with adjuvant
anthracycline: results from a randomized
phase 3 study
Sparano J, Makhson A, Semiglazov V, Tjulandin S, Balashova O, Bondarenko
I, Bogdanova N, Chatikhine V, Zhuang S, Xiu L, Yuan Z, Rackoff W. Albert
Einstein Coll of Med, New York, NY; City Onc Hosp#62, Moscow, Russian
Federation; NN Petrov Res Inst of Onc, St-Petersburg, Russian Federation; NN
Blokhin Can Res Cntr, Moscow, Russian Federation; Regional Onc Dispensary,
Dnepropetrovsk, Ukraine; State Med Acad, Dnepropetrovsk, Ukraine; PA
Herzen Onc Res Inst, Moscow, Russian Federation; OrthoBiotech Onc R&D,
J&JPRD, Raritan, NJ. |
| |
|
| 11:30 |
81. A prospectively planned pathology study
within the TEAM trial confirms that Progesterone
receptor expression is prognostic but is not
predictive for differential response to exemestane
versus tamoxifen.
Bartlett JMS, Brookes CL, Billingham LJ, Campbell FM,
Grant M, Hasenburg A, Hille ETM, Kay C, Kieback
D, Markopoulos C, Kranenbarg EM-K, Mallon EA,
Paridaens R, Robson T, Seynaeve C, van de Velde CJH,
Rea D; Endocrine Cancer Group Edinburgh University
United Kingdom; University of Birmingham, United
Kingdom; University Hospital Freiburg, Germany;
Erasmus MC Rotterdam Netherlands; Helios Medical
Center AUE Germany, Athens University Medical
School Greece; UZ Gasthuisberg Leuven, Belgium;
LUMC Leiden, Netherlands; Western Infirmary
Glasgow, United Kingdom. |
| |
|
| 11:45 |
82. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) → 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial
Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Jukkola-Vuorinen A, Asola R, Kokko R, Ahlgren J, Bono P, Tanner M, Lindman H for The Finnish Breast Cancer Group.
|
| |
|
| 12:00 |
ADJOURNMENT, 31st Annual San
Antonio Breast Cancer Symposium |
|
|
|
|
Home
Registration
Schedule at a Glance
